By Gary M. White, MD

Note: This is a summary only. Please consult the latest information when prescribing.

Adalimumab and Psoriasis

Trade Name



Black Box Warnings

SERIOUS INFECTION Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.

MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including HUMIRA.

Dose for Psoriasis

80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.

Pregnancy Category


Nursing Mothers

Limited data from published literature indicate that adalimumab is present in low levels in human milk and is not likely to be absorbed by a breastfed infant. However, no data is available on the absorption of adalimumab from breast milk in newborn or preterm infants. Caution should be exercised when HUMIRA is administered to a nursing woman.


Home | FAQs | Use of Images | Privacy Policy | Contact

It is not the intention of to provide specific medical advice, diagnosis or treatment. only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.